- Cyclerion Therapeutics (CYCN) Q2 results: Revenues: $1.6M.
- Net loss: ($32.3M) (-8.4%); loss/share: ($1.18) (-8.3%); Quick Assets: $141M.
- Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019.
- Phase 2 study of olinciguat in sickle cell disease on track for data readout in mid-2020.
- Phase 1 study of IW-6463, central nervous system penetrant sGC stimulator is on track for data readout in Q4 2019.
- Cyclerion will host a webcast event focused on praliciguat cardiometabolic programs on September 17 in New York City ahead of anticipated clinical results.
- Previously: Cyclerion Therapeutics EPS misses by $0.34 (Aug. 12)
Cyclerion reports Q2 results; updates data readouts in next 12 months
Recommended For You
More Trending News
About CYCN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CYCN | - | - |
Cyclerion Therapeutics, Inc. |